EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-term outcomes of patients with IgA nephropathy in the German CKD cohort

Eleni Stamellou iD, Jennifer Nadal, Bruce Hendry, Alex Mercer, Claudia Seikrit, Wibke Bechtel-Walz, Matthias Schmid, Marcus J Moeller, Mario Schiffer, Kai-Uwe Eckardt iD, Rafael Kramann iD, Jürgen Floege und 1 weitere

Clinical Kidney Journal · 01.08.2024 · 17 (8)

DOI: 10.1093/ckj/sfae230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 22.07.2024. Verfasst von Eleni Stamellou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Clinical Immunology, RWTH Aachen University Hospital, Aachen, Germany. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The importance of albuminuria as opposed to proteinuria in predicting kidney outcomes in primary immunoglobulin A nephropathy (IgAN) is not well established.

Methods

From 2010 to 2012, 421 patients with biopsy-proven IgAN have been enrolled into the German Chronic Kidney Disease (GCKD) cohort, a prospective observational cohort study (N = 5217). Adjudicated endpoints include a composite kidney endpoint (CKE) consisting of eGFR decline >40%, eGFR <15 ml/min/1.73 m2 and initiation of kidney replacement therapy; the individual components of the CKE; and combined major adverse cardiac events (MACE), including non-fatal myocardial infarction, non-fatal stroke and all-cause mortality. The associations between the incidence of CKE and baseline factors, including demographics, laboratory values and comorbidities were analysed using the Cox proportional hazards regression model.

Results

The mean age of IgAN patients at baseline was 51.6 years (± 13.6) and 67% were male. The patient-reported duration of disease at baseline was 5.9 ± 8.1 years. Baseline median urine albumin:creatinine ratio (UACR) was 0.4 g/g [interquartile range (IQR) 0.1–0.8] and mean eGFR was 52.5 ± 22.4 ml/min/1.73 m2. Over a follow-up of 6.5 years, 64 (15.2%) patients experienced a >40% eGFR decline, 3 (0.7%) reached eGFR <15 ml/min/1.73 m2, 53 (12.6%) initiated kidney replacement therapy and 28% of the patients experienced the CKE. Albuminuria, with reference to <0.1 g/g, was most associated with CKE. Hazard ratios (HRs) at UACRs of 0.1–0.6 g/g, 0.6–1.4 g/g, 1.4–2.2 g/g and >2.2 g/g were 2.03 [95% confidence interval (CI) 1.02–4.05], 3.8 (95% CI 1.92–7.5), 5.64 (95% CI 2.58–12.33) and 5.02 (95% CI 2.29–11-03), respectively. Regarding MACE, the presence of diabetes [HR 2.53 (95% CI 1.11–5.78)] was the most strongly associated factor, whereas UACR and eGFR did not show significant associations.

Conclusion

In the GCKD IgAN subcohort, more than every fourth patient experienced a CKE event within 6.5 years. Our findings support the use of albuminuria as a surrogate to assess the risk of poor kidney outcomes.

Schlagwörter

Stichwörter der Autor:innen

CKDIgA nephropathyalbuminuriaglomerulonephritisproteinuria

Autor:innen und Institutionen

  • Division of Nephrology and Clinical Immunology, RWTH Aachen University Hospital, Aachen, Germany.
  • Department of Nephrology, School of Medicine, University of Ioannina, Ioannina, Greece.
  • Department of Medical Biometry, Informatics and Epidemiology, Faculty of Medicine, University Hospital Bonn, Bonn, Germany.
  • Travere Therapeutics, San Diego, CA, USA.
  • JAMCO Pharma Consulting, Stockholm, Sweden.
  • Department of Medicine IV, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

ORCID-Profile: Eleni Stamellou, Kai-Uwe Eckardt, Rafael Kramann

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Stamellou, E., Nadal, J., Hendry, B., Mercer, A., Seikrit, C., Bechtel-Walz, W., Schmid, M., Moeller, M. J., Schiffer, M., Eckardt, K. U., Kramann, R., Floege, J., & GCKD study investigators (2024). Long-term outcomes of patients with IgA nephropathy in the German CKD cohort. Clinical Kidney Journal, 17(8). https://doi.org/10.1093/ckj/sfae230

Vancouver

Stamellou E, Nadal J, Hendry B, Mercer A, Seikrit C, Bechtel-Walz W, et al. Long-term outcomes of patients with IgA nephropathy in the German CKD cohort. Clinical Kidney Journal. 2024;17(8). doi:10.1093/ckj/sfae230

BibTeX
@article{Stamellou2024,
  author = {Stamellou, Eleni and Nadal, Jennifer and Hendry, Bruce and Mercer, Alex and Seikrit, Claudia and Bechtel-Walz, Wibke and Schmid, Matthias and Moeller, Marcus J and Schiffer, Mario and Eckardt, Kai-Uwe and Kramann, Rafael and Floege, Jürgen and GCKD study investigators, GCKD study investigators},
  title = {Long-term outcomes of patients with IgA nephropathy in the German CKD cohort},
  journal = {Clinical Kidney Journal},
  year = {2024},
  volume = {17},
  number = {8},
  doi = {10.1093/ckj/sfae230}
}
Kostenlos starten →